Abstracts Archive - Page 97 of 2607 - ACR Meeting Abstracts

Abstract Number: 0926 • ACR Convergence 2025
Discovery and Characterization of SIM0711: a Potent and Selective IRAK4 PROTAC with Improved Efficacy and Safety
Minyun Zhou¹, Peng Gu², Mengyu Wang³, Yuxi Yan², Li Sun³, Yiling Chen³, Xin Wang³, Feng Tang¹, Shunwei Zhu² and Xiaofeng Zhao⁴, ¹State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing, ²State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), ³State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ⁴State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic)
Background/Purpose: IRAK4 plays a pivotal role in the innate immune response by acting downstream of Toll-like receptors (TLRs) and the interleukin-1 receptor (IL-1R), with both…
Abstract Number: 0898 • ACR Convergence 2025
Distinct B Cell and Plasma Cell Immunosuppression Strategies Eliminate Antigen-Specific Cells of the B Lineage
Carley Tasker¹, Nicholas Giovannone², Nyanza Rothman², Sofia Caruso², Julia Provino², Laura Johnsen², Johanna Napetschnig², Jamie Orengo¹, Christos Kyratsous², Andre Limnander¹, Katherine Cygnar² and Andrew Baik², ¹Regeneron, Tarrytown, NY, ²Regeneron Pharmaceuticals, Tarrytown
Background/Purpose: Development of effective targeting strategies to eliminate sources of antibody production presents utility in the treatment of autoimmune diseases driven by pathogenic autoantibodies. Furthermore,…
Abstract Number: 0679 • ACR Convergence 2025
Inhibition of TGFb3 in Systemic Sclerosis Patients Does Not Result in TGFb Pathway Modulation in Skin Biopsies or Circulation
Parisa Mazrooei, Xuting Rebecca Sheng, Xiaoyun Yang, Lyrialle Han, Samira Jamalian, Daniel Repplinger, Jingxuan He, Evelin Logis, Jeongsup Shim, Angela Hendricks, Lena Wang, Andrew Thorley and Sara Glickstein, Genentech/Roche, South San Francisco
Background/Purpose: There are 3 isoforms of Transforming Growth Factor Beta (TGFb), a cytokine frequently upregulated in fibrosis. Chronic targeting of TGFb1 and TGFb2 for fibrotic…
Abstract Number: 0696 • ACR Convergence 2025
Impact of Autologous Stem Cell Transplantation on Cardiac Performance in Systemic Sclerosis
Jeska de Vries-Bouwstra¹, Jingjing He², Xu Wang², Saad Ahmed², Jeroen J. Bax² and Nina Ajmone Marsan², ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands
Background/Purpose: Myocardial involvement in systemic sclerosis (SSc) represents a severe complication with a poor prognosis; however, compromised cardiac function also heightens the risk of life-threatening…
Abstract Number: 0677 • ACR Convergence 2025
Increased incidence of sudden cardiac death in systemic sclerosis: estimate & correlates.
Jessica Fairley¹, Elizabeth Paratz², Dylan Hansen³, Susanna Proudman⁴, Joanne Sahhar⁵, Gene-Siew Ngian⁶, Diane Apostolopoulos⁶, Jennifer Walker⁷, Lauren Host⁸, Wendy Stevens¹, Andre La Gerche², Mandana Nikpour⁹ and Laura Ross¹, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, ³St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, ⁴The University of Adelaide, Adelaide, Victoria, Australia, ⁵Monash Health, Melbourne, Victoria, Australia, ⁶Monash University, Melbourne, Victoria, Australia, ⁷Flinders University, Adelaide, Victoria, Australia, ⁸Fiona Stanley Hospital, Perth, Victoria, Australia, ⁹University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia
Background/Purpose: The incidence of sudden cardiac death (SCD) is suspected to be increased in systemic sclerosis (SSc). However, data describing SCD incidence in SSc are…
Abstract Number: 0633 • ACR Convergence 2025
Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis (AAV) and Systemic Lupus Erythematosus (SLE): A Comparative Analysis
Sai Shanmukha Sreeram Pannala¹, Medha Rajamanuri², Srikar Sama³, Fares Saliba⁴, Omar Mourad⁵, Elizabeth Fagin⁶, Koushik Varma Sangaraju⁷, Veena Katikineni⁸ and Anastasia Slobodnick⁹, ¹Northwell health/Staten Island university Hospital, new york city, NY, ²Southern Illinois University School of Medicine, Springfield, IL, ³University of California San Francisco Fresno, Fresno, CA, ⁴Staten Island University Hospital, Staten Island, NY, ⁵Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, Staten Island, NY, ⁶Staten Island University Hospital, Teaneck, NJ, ⁷St. Luke's University Health Network, Bethlehem, PA, ⁸Desert Orthopaedic and Rheumatologic Institute, Apple Valley, CA, ⁹Northwell, Staten Island, NY
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a rare but severe complication in Systemic Lupus Erythematosus (SLE), occurring in up to one-third of cases at disease…
Abstract Number: 0927 • ACR Convergence 2025
Improved Skin Lymphatic Flow Regulates Dendritic Cells to Mediate Lymph Node Fibroblast Alterations and Immune Responses in Lupus
Mir Howlader¹ and Theresa Lu², ¹Weill Cornell Medical College, Brooklyn, NY, ²Hospital for Special Surgery, NEW YORK, NY
Background/Purpose: Lupus is a chronic autoimmune disease with a global loss of self-tolerance. Lupus patients are photosensitive where exposure to even ambient sunlight results in…
Abstract Number: 0913 • ACR Convergence 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
Veronica Campbell¹, Yi Zhang¹, Virginia Massa¹, Jordan Leedberg¹, Erik Corcoran¹, Emily Lurier¹, Ryan Camire², Chris Carroll¹, Chris Ho¹, Dapeng Chen¹, Bradley Enerson¹, Revonda Mehovic¹, Ziyan Zhao¹, Lincoln Howarth¹, Susanne Breitkopf¹, Sarah Martinez¹, Melissa Ford¹, Xue Fei¹, Murugappan Sathappa¹, Juliet Williams³, Matthew Weiss³, Arsalan Shabbir³ and Nello Mainolfi⁴, ¹Kymera Therapeutics, Watertown, MA ⁰²⁴⁷², ²Kymera Therapeutics, Watertown, MA ⁰²⁴⁷², MA, ³Kymera Therapeutics, Watertown, ⁴Kymera Therapeutics, Watertown, MA
Background/Purpose: IRF5 is a transcription factor and regulator of immune responses activated downstream of pattern recognition receptors, in particular endosomal toll-like receptors (TLR), TLR7, TLR8…
Abstract Number: 0915 • ACR Convergence 2025
A fusion of TACI variant and anti-IFNAR antibody with greater therapeutic effect on related autoimmune disease models
Yuhao Qin¹, Huan Wang¹, Han Gao¹, Chongqi Zhang¹, Chengpan Wang¹, yanru fan¹, wei ye¹, yuan lin¹, Lu Su², Wenming Ren¹ and cheng liao¹, ¹Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China (People's Republic), ²Jiangsu Hengrui Pharmaceuticals, Shanghai, Shanghai, China
Background/Purpose: Pathological elevation of type I interferon (IFN-I) , B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) has been robustly documented across multiple autoimmune…
Abstract Number: 0652 • ACR Convergence 2025
Evolution and Readiness: Preparing for Cell Therapy in Lupus Trials, A LuCIN Network Evaluation
Brandon Jackson¹, Saira Sheikh², Roberto Caricchio³, Taylor Irons⁴, Maria Dall'Era⁵, Amit Saxena⁶, Alfred Kim⁷, Jose Rubio⁸, Sasha Bernatsky⁹, David Goddard¹⁰, Fotios Koumpouras¹¹, Aimee Williams¹², Maya Merrell¹³, Jennifer Meriwether¹⁴ and Stacie Bell¹⁵, ¹Lupus Therapeutics, Miami, FL, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of Massachusetts Chan Medical School, Worcester, MA, ⁴Lupus Therapeutics, Houston, TX, ⁵Division of Rheumatology, University of California, San Francisco, CA, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Washington University School of Medicine, St. Louis, MO, ⁸University of Alabama at Birmingham, Hoover, AL, ⁹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰NYU Langone Grossman SOM, Brooklyn, NY, ¹¹Yale School of Medicine, New Haven, CT, ¹²Lupus Therapeutics, Raleigh, NC, ¹³Lupus Therapeutics, Charleston, SC, ¹⁴Lupus Therapeutics, Westminster, CO, ¹⁵Lupus Therapeutics, Lakewood, CO
Background/Purpose: Lupus Therapeutics (LT), the clinical affiliate of the Lupus Research Alliance, oversees the premier North American Lupus Clinical Investigators Network (LuCIN). As cell therapy…
Abstract Number: 0893 • ACR Convergence 2025
Transcriptomic insights into GCA compared to clinically diverse controls: Inflammation, Aging, Therapeutic Targets and the role of SPP1 in the temporal artery
Ingrid Lindquist¹, Alisha Eskew², Dongsoek Choi³, David Wilson⁴, Diva Salomao⁵, Hillary Stiefel⁴, Daniel Albert⁴, Kiana Vakil-Gilani⁶, Daniela Ghetie⁷, James Rosenbaum⁸ and Marcia Friedman⁹, ¹Portland VA Medical Center, Portland, OR, ²OHSU, Portland, OR, ³OHSU, Portland, ⁴Casey Eye Institute OHSU, Portland, OR, ⁵Mayo Clinic, Rochester, MN, ⁶PeaceHealth, Portland, OR, ⁷OHSU, Lake Oswego, OR, ⁸Legacy Devers Eye Institute, Portland, OR, ⁹Immpact Bio, Beaverton, OR
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in people over 50 years old and is a clinical diagnosis bolstered by non-specific inflammatory…
Abstract Number: 0911 • ACR Convergence 2025
A Novel FcRn × Albumin Bispecific Antibody Demonstrates Extended Half-life and Deep IgG Reduction in Preclinical Mouse Models
Hang Su¹, Lulu Li¹, Zenglin Pei¹, Barry Duplantis², Yuhao Wang², Yi Li¹ and Quan Yu¹, ¹Ailux, Shanghai, China (People's Republic), ²Ailux, Boston, MA
Background/Purpose: Autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s syndrome are characterized by elevated levels of pathogenic autoantibodies that drive inflammation. The…
Abstract Number: 0920 • ACR Convergence 2025
Functional Characterization of NEMO-NDAS Causing Variants in Patients’ PBMCs and in Wildtype and Mutant U937 Cells
Elizabeth Morgan¹, Bin Lin², Sara alehashemi¹, Adriana de Jesus¹, Keith Kauffman³, Christopher Friend¹, Farzana Bhuyan¹, Kader Gedik¹, Kat Uss¹, Lauren Krausfeldt⁴, Jason Brenchley⁵, Zoran Gucev⁶, Kathryn Cook⁷, Vafa Mammadova⁸, Gulnara Nasrullayeva⁸, Mariana Correia Marques⁹, Abigail Bosk¹⁰, Brian Nolan¹¹, Scott Canna¹², Maude Tusseau¹³, Andrea Bohrer¹⁴, Katrin Mayer-Barber¹⁵, Timothy Moran¹⁶, Andrew Oler⁴, Daniel Barber³ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Diseases Section (TADS), Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, NIH, Bethesda, MD, ²NIH, Bethesda, MD, ³T-Lymphocyte Biology Section, Laboratory of Parasitic Diseases, NIAID, NIH, Bethesda, MD, ⁴Bioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, NIAID, NIH, Bethesda, MD, ⁵Barrier Immunity Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, ⁶University Children's Hospital, Medical Faculty Skopje, Skopje, Macedonia, ⁷Akron Children’s Hospital, Akron, OH, ⁸Azerbaijan Medical University, Baku, Azerbaijan, ⁹Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁰Children’s National Hospital, Washington DC, ¹¹Lurie Children’s Hospital, Chicago, ¹²Children's Hospital of Philadelphia, Philadelphia, PA, ¹³Hôpital Femme-Mère-Enfant, Bron, France, ¹⁴Inflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, NIH, Bethesda, MD, ¹⁵Inflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology (LCIM), Bethesda, MD, ¹⁶University of North Carolina School of Medicine, Chapel Hill, NC
Background/Purpose: NEMO-deleted 5 autoinflammatory syndrome (NEMO-NDAS) is an inflammatory disease caused by mosaic splice-site variants that lead to exon 5 skipping in IKBKG, encoding NEMO.…
Abstract Number: 0922 • ACR Convergence 2025
Phenotypic and Transcriptomic Divergence in C3 Glomerular Mouse Models: Insights into Immune and Sex Correlates
Juan Liang¹ and kaiyuan zi², ¹Gempharmatech, Nanjing, Jiangsu, China, ²Gempharmatech, Nanjing, Jiangsu, Jiangsu, China
Background/Purpose: Complement component C3 plays a central role in the alternative pathway (AP) and is implicated in the pathogenesis of C3 glomerulopathy (C3G), a rare…
Abstract Number: 0921 • ACR Convergence 2025
Fibrinogen Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Promotes Pro-Inflammatory Macrophage Differentiation Through p38 and NF-κB Signaling
Hannah Johnson¹, Wenxian Zhou², Michael Duryee¹, Carlos Hunter¹, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE
Background/Purpose: Citrulline (CIT) and malondialdehyde-acetaldehyde (MAA) co-adduct native proteins in RA tissues to create a dual pro-inflammatory and pro-fibrotic milieu. Our previous work demonstrated that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].